Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.38 |
| ▸ | PRKDC | P78527 | 2/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386768 | 0.92 | PDE4D (0.41) | PDE4DPDE4APDE4BPDE4CKDM1A | |
| SCHEMBL5483281 | 0.83 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CKDM1A | |
| SCHEMBL2885286 | 0.80 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CKDM1A | |
| SCHEMBL2885282 | 0.80 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CKDM1A | |
| SCHEMBL2885287 | 0.80 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CKDM1A | |
| SCHEMBL4289987 | 0.80 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL2264614 | 0.79 | PDE10A (0.42) | PDE4DPDE4APDE4BPDE4CCHEK1 | |
| SCHEMBL7427914 | 0.79 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CKDM1A | |
| SCHEMBL7427912 | 0.79 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CKDM1A | |
| SCHEMBL7206837 | 0.78 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4CKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202880-B2 | 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-06-19 | — | — | US | claimed |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | NYCOMED GMBH (DE) | 2009-07-02 | — | — | US | claimed |
| US-7423046-B2 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | NYCOMED GMBH (DE) | 2008-09-09 | — | — | US | claimed |
| EP-1536798-B1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-02-07 | — | — | EP | claimed |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALANA PHARMA AG (DE) | 2005-10-27 | — | — | US | claimed |
| US-8202880-B2 | 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | NYCOMED GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-7423046-B2 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | NYCOMED GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| EP-1536798-B1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALANA PHARMA AG (DE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4D 7/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4D 6/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.